Cancer
Malignant Kidney Neoplasm
CI-CAN-00003171Explore in graph →
Top-level453 active trials17 approved drugs80 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer
CI-CAN-00003171Explore in graph →
Clinical trials
2,143 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (339)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05621837 | Quantifying Systemic Immunosuppression to Personalize Cancer Therapy(Serpentine) | recruiting | — | 1,000 | Fondazione IRCCS Istituto Nazionale dei Tumori, MilanoOTHER | 1 | May 2, 2025 | clinicaltrials |
| NCT06751498 | The Value of a Convolutional Neural Network-Based Renal Artery Perfusion Model in Predicting Renal Function After Partial Nephrectomy: A Prospective Study | recruiting | — | 300 | Shao PengfeiOTHER |
| 1 |
| Apr 17, 2025 |
| clinicaltrials |
| NCT06926374 | Prospective Evaluation of Cornerstone Robotics Sentire Surgical System in Major Gastrointestinal and Urologic Surgery | recruiting | N/A | 90 | Chinese University of Hong KongOTHER | 1 | Apr 16, 2025 | clinicaltrials |
| NCT03592472 | A Study of Pazopanib With or Without Abexinostat in Patients With Locally Advanced or Metastatic Renal Cell Carcinoma (RENAVIV) | recruiting | Phase 3 | 413 | Xynomic Pharmaceuticals, Inc.INDUSTRY | 6 | Apr 13, 2025 | clinicaltrials |
| NCT06908902 | Prospective Study on the Safety and Efficacy of Robot-Assisted Laparoscopic Partial Nephrectomy With Renal Artery Off-Clamp in the Treatment of cT1 Renal Tumors | recruiting | N/A | 60 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Apr 3, 2025 | clinicaltrials |
| NCT06536439 | Planning Operative Strategy Using a Digital Renal Artery Clamping Tool(PODRACING) | recruiting | N/A | 235 | University Hospital, GhentOTHER | 1 | Apr 1, 2025 | clinicaltrials |
| NCT06714916 | Optimising Renal Tumour Management Through Artificial Intelligence Modules | recruiting | — | 2,100 | Shao PengfeiOTHER | 1 | Mar 19, 2025 | clinicaltrials |
| NCT06883539 | A Phase I Study of LXP1788 Injection with Advanced Solid Tumors. | recruiting | Phase 1 | 24 | LaunXP Biomedical Co., Ltd.INDUSTRY | 1 | Mar 19, 2025 | clinicaltrials |
| NCT04510129 | A Multicenter Cancer Biospecimen Collection Study | recruiting | — | 1,650 | Cofactor Genomics, Inc.INDUSTRY | 1 | Mar 12, 2025 | clinicaltrials |
| NCT05231655 | Ex VIvo DEtermiNed Cancer Therapy(EVIDENT) | recruiting | — | 600 | Sheffield Teaching Hospitals NHS Foundation TrustOTHER | 1 | Feb 24, 2025 | clinicaltrials |
| NCT03382158 | International PPB/DICER1 Registry | recruiting | — | 3,400 | Children's Hospitals and Clinics of MinnesotaOTHER | 1 | Jan 30, 2025 | clinicaltrials |
| NCT06364631 | CARE1 Pragmatic Clinical Trial(CARE1) | recruiting | Phase 3 | 1,250 | Gustave Roussy, Cancer Campus, Grand ParisOTHER | 4 | Jan 16, 2025 | clinicaltrials |
| NCT06290427 | Comparison of Outcomes of Multiple Platforms for Assisted Robotic-Kidney (COMPAR-K)(COMPAR-K) | recruiting | N/A | 30 | Azienda Ospedaliera Universitaria Integrata VeronaOTHER | 1 | Jan 3, 2025 | clinicaltrials |
| NCT06750419 | 89Zr-TLX250 for PET/CT Imaging of ccRCC - ZIRCON-CP Study | recruiting | Phase 3 | 82 | Telix Pharmaceuticals (Innovations) Pty LimitedINDUSTRY | 1 | Dec 27, 2024 | clinicaltrials |
| NCT06281678 | A Study of IBI363 in Subjects with Advanced Solid Malignancies | recruiting | Phase 2 | 178 | Innovent Biologics (Suzhou) Co. Ltd.INDUSTRY | 1 | Dec 19, 2024 | clinicaltrials |
| NCT06730672 | An Exploratory Study on the Failure of Immunotherapy With Voronib Combined With Everolimus | recruiting | Phase 2 | 80 | Sun Yat-sen UniversityOTHER | 1 | Dec 18, 2024 | clinicaltrials |
| NCT06016075 | Investigation of Differential Biology of Benign and Malignant Renal Masses Using Advanced Magnetic Resonance Imaging Techniques(IBM-Renal) | recruiting | N/A | 30 | University of CambridgeOTHER | 1 | Dec 5, 2024 | clinicaltrials |
| NCT06211114 | Study to Evaluate the Efficacy and Safety of Immunotherapy With Axitinib in Advanced Collecting Duct Carcinoma | recruiting | Phase 2 | 30 | Peking University Cancer Hospital & InstituteOTHER | 1 | Nov 26, 2024 | clinicaltrials |
| NCT05824975 | A Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patients with Advanced Solid Tumors (KEYNOTE-G08) | recruiting | Phase 1 / Phase 2 | 358 | GI Innovation, Inc.INDUSTRY | 2 | Nov 25, 2024 | clinicaltrials |
| NCT05572216 | A CCafU-UroCCR Randomized Trial: 3D Image-Guided Robot-AssisTEd Partial Nephrectomy for Renal Complex Tumor (UroCCR N°99)(ACCURATE) | recruiting | N/A | 694 | University Hospital, GrenobleOTHER | 1 | Nov 18, 2024 | clinicaltrials |
| NCT04787042 | Phase 1a and Phase 2 Study for Safety, Preliminary Efficacy, PK and PD of ST-067 | recruiting | Phase 1 / Phase 2 | 316 | Simcha IL-18, Inc.INDUSTRY | 1 | Nov 15, 2024 | clinicaltrials |
| NCT06690697 | Combination of Toripalimab and JS004 Therapy for ccRCC | recruiting | Phase 2 | 80 | Fudan UniversityOTHER | 1 | Nov 15, 2024 | clinicaltrials |
| NCT06519760 | 68Ga-C1 PET/ CT Imaging in Clear Cell Renal Cell Carcinoma | recruiting | N/A | 200 | Peking University First HospitalOTHER | 1 | Nov 7, 2024 | clinicaltrials |
| NCT05810571 | Comparison of Postoperative Analgesic Efficacy of the Erector Spina Plane Block and Quadratus Lumborum Block in Open Nephrectomy: a Prospective Randomized Clinical Study | recruiting | N/A | 60 | Kocaeli UniversityOTHER | 1 | Oct 26, 2024 | clinicaltrials |
| NCT06652009 | Radical Radiotherapy Versus Radical Surgery for UTUC | recruiting | — | 60 | Peking University First HospitalOTHER | 1 | Oct 22, 2024 | clinicaltrials |
| NCT05878964 | Evaluation of Skin Health and QoL in Pts Receiving Anti-PD1/PDL1/CTLA4 or CDK Inhibitors.(SkinHealth) | recruiting | — | 420 | Fondazione Policlinico Universitario Agostino Gemelli IRCCSOTHER | 1 | Oct 4, 2024 | clinicaltrials |
| NCT06613269 | 68Ga-NY104 PET/CT Guided Radiation Therapy in CcRCC.(NYCRRT) | recruiting | Phase 2 | 40 | Peking Union Medical College HospitalOTHER | 1 | Sep 27, 2024 | clinicaltrials |
| NCT06259552 | A Study of SPX-303, a Bispecific Antibody Targeting LILRB2 and PD-L1 in Patients With Solid Tumors(SPX-303) | recruiting | Phase 1 | 232 | SparX Biotech(Jiangsu) Co., Ltd.OTHER | 1 | Sep 24, 2024 | clinicaltrials |
| NCT06399419 | CBM588 Capsules in Combination With Nivolumab and Ipilimumab for the Treatment of Advanced Stage Kidney Cancer | recruiting | Phase 1 | 28 | Osel, Inc.INDUSTRY | 1 | May 30, 2024 | clinicaltrials |
| NCT05539677 | Biobank and Register of Patients With Agresive Tumors for Translational and Analytical Research(REGATA) | recruiting | — | 1,000 | N.N. Petrov National Medical Research Center of OncologyOTHER | 1 | May 6, 2024 | clinicaltrials |
| NCT05868174 | Combination of 177Lu-TLX250 and Peposertib in Patients With Carbonic Anhydrase IX -Expressing Solid Tumors | recruiting | Phase 1 | 36 | Telix Pharmaceuticals (Innovations) Pty LimitedINDUSTRY | 1 | May 1, 2024 | clinicaltrials |
| NCT03749980 | MyVHL: Patient Natural History Study(MyVHL) | recruiting | — | 10,000 | Joshua Mann, MPHOTHER | 1 | Apr 26, 2024 | clinicaltrials |
| NCT06336187 | European Active Surveillance of Renal Cell Carcinoma Study (EASE RCC Study)(EASE) | recruiting | — | 400 | Azienda Ospedaliero Universitaria Maggiore della CaritaOTHER | 1 | Apr 10, 2024 | clinicaltrials |
| NCT06265025 | GM103 Intratumoral Injection in Patients With Locally Advanced, Unresectable, Refractory and/or Metastatic Solid Tumors | recruiting | Phase 1 / Phase 2 | 125 | GeneMedicine Co., Ltd.INDUSTRY | 1 | Mar 21, 2024 | clinicaltrials |
| NCT06278506 | Resection or Ablation of Small Kidney Tumors(RESTART) | recruiting | N/A | 300 | Karolinska University HospitalOTHER | 1 | Feb 26, 2024 | clinicaltrials |
| NCT06041555 | MRI Guided Radiotherapy and Radiobiological Data: the ISRAR Database (Irm Sequences for Radiobiological Adaptative Radiotherapy)(ISRAR) | recruiting | — | 600 | Hospices Civils de LyonOTHER | 1 | Feb 20, 2024 | clinicaltrials |
| NCT03414827 | Genetic Evaluation of Renal Cell Carcinoma; Predicting Biomarkers for Renal Cell Carcinoma | recruiting | — | 120 | Zealand University HospitalOTHER | 1 | Jan 30, 2024 | clinicaltrials |
| NCT03857373 | Renal Cancer Detection Using Convolutional Neural Networks(RCCCNN) | recruiting | — | 5,000 | Nessn AzawiOTHER | 1 | Jan 30, 2024 | clinicaltrials |
| NCT06211790 | Proteomic Guided First-line Precision Treatment of Renal Clear Cell Carcinoma | recruiting | Phase 2 | 66 | Fudan UniversityOTHER | 1 | Jan 18, 2024 | clinicaltrials |
| NCT06194669 | Mechanisms of Somatic Mutation and Tumor Initiation in Pre-malignant Kidney Tubule Cells(SoMuKT) | recruiting | — | 50 | IRCCS San RaffaeleOTHER | 1 | Jan 10, 2024 | clinicaltrials |
| NCT06010875 | A Clinical Research About CD70-targeted CAR-T in the Treatment of CD70-positive Advanced/Metastatic Solid Tumors | recruiting | Phase 1 | 48 | Chongqing Precision Biotech Co., LtdINDUSTRY | 1 | Nov 8, 2023 | clinicaltrials |
| NCT05753839 | The Role of Cytoreductive Nephrectomy in Metastatic Renal Cell Carcinoma in Immuno-oncology Era: SEVURO-CN Trial(SEVURO-CN) | recruiting | N/A | 40 | Yonsei UniversityOTHER | 1 | Jun 22, 2023 | clinicaltrials |
| NCT05817903 | Axitinib Intensification Plus Nivolumab or Nivolumab Alone After Nivolumab Plus Ipilimumab in mRCC Patients(AxIn) | recruiting | Phase 2 | 118 | Consorzio OncotechOTHER | 1 | May 8, 2023 | clinicaltrials |
| NCT05589207 | Predicting Model Based on Evidence-based Pathological Diagnose Criteria for RCC Tumor Thrombus With IVC Wall Invasion | recruiting | — | 232 | Peking University Third HospitalOTHER | 1 | Feb 21, 2023 | clinicaltrials |
| NCT04625556 | Development of Urologic Registry for Personalized Medicine in Patients With Urologic Malignant Diseases by Analyzing Microbiome | recruiting | — | 3,000 | Yonsei UniversityOTHER | 1 | Jan 31, 2023 | clinicaltrials |
| NCT05363657 | International REgistry of COnservative or Radical Treatment of Localized Kidney Tumors(i-RECORd) | recruiting | — | 10,000 | Azienda Ospedaliero-Universitaria CareggiOTHER | 13 | May 6, 2022 | clinicaltrials |
| NCT05037825 | The Gut Microbiome and Immune Checkpoint Inhibitor Therapy in Solid Tumors(PARADIGM) | recruiting | — | 800 | VastBiomeINDUSTRY | 1 | Apr 27, 2022 | clinicaltrials |
| NCT05214885 | Novel Biomarkers of Hypoxia and Metabolism in Clear Cell Renal Cell Carcinoma | recruiting | — | 300 | Qianfoshan HospitalOTHER | 1 | Mar 9, 2022 | clinicaltrials |
| NCT04712305 | Urine Omics Predicting IO Therapy Responses in mRCC Patients | recruiting | — | 400 | National Taiwan University HospitalOTHER | 1 | Jan 20, 2022 | clinicaltrials |
Data updated 23 days agoSource updated May 2, 2025source: clinicaltrials